Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ruff

Showing results (81-90 of 224) with videos related to

Pageof 23
Sort By:
JAMA Cardiology|October 6, 2016
Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal|May 15, 2015
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trialJ Steffel, R P Giugliano, E Braunwald, et al.
Journal of the American College of Cardiology|March 5, 2021
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial FibrillationJan Steffel, Christian T Ruff, Ophelia Yin, et al.
Clinical Cardiology|January 24, 2014
Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain studyDevraj Sukul, Marc P Bonaca, Christian T Ruff, et al.
American Heart Journal|December 19, 2015
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trialElizabeth A Magnuson, Katherine Vilain, Kaijun Wang, et al.
American Heart Journal|September 21, 2015
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trialBram J Geller, Robert P Giugliano, Eugene Braunwald, et al.
Journal of the American Heart Association|February 25, 2016
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 TrialHaiyan Xu, Christian T Ruff, Robert P Giugliano, et al.
Circulation. Cardiovascular Quality and Outcomes|November 5, 2020
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 TrialKatherine Vilain, Haiyan Li, Wingham J Kwong, et al.
Journal of the American College of Cardiology|January 17, 2024
Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing LipoproteinsNicholas A Marston, Giorgio E M Melloni, Sabina A Murphy, et al.
Journal of Thrombosis and Thrombolysis|March 27, 2012
Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest painAmit N Vora, Marc P Bonaca, Christian T Ruff, et al.
Pageof 23

Showing results (81-90 of 224) with videos related to

Sort By:
Pageof 23
JAMA Cardiology|October 6, 2016
Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal|May 15, 2015
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trialJ Steffel, R P Giugliano, E Braunwald, et al.
Journal of the American College of Cardiology|March 5, 2021
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial FibrillationJan Steffel, Christian T Ruff, Ophelia Yin, et al.
Clinical Cardiology|January 24, 2014
Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain studyDevraj Sukul, Marc P Bonaca, Christian T Ruff, et al.
American Heart Journal|December 19, 2015
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trialElizabeth A Magnuson, Katherine Vilain, Kaijun Wang, et al.
American Heart Journal|September 21, 2015
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trialBram J Geller, Robert P Giugliano, Eugene Braunwald, et al.
Journal of the American Heart Association|February 25, 2016
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 TrialHaiyan Xu, Christian T Ruff, Robert P Giugliano, et al.
Circulation. Cardiovascular Quality and Outcomes|November 5, 2020
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 TrialKatherine Vilain, Haiyan Li, Wingham J Kwong, et al.
Journal of the American College of Cardiology|January 17, 2024
Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing LipoproteinsNicholas A Marston, Giorgio E M Melloni, Sabina A Murphy, et al.
Journal of Thrombosis and Thrombolysis|March 27, 2012
Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest painAmit N Vora, Marc P Bonaca, Christian T Ruff, et al.
Pageof 23